Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Thomas YauVittorina ZagonelArmando SantoroMirelis Acosta-RiveraSu Pin ChooAna María MatillaAiwu Ruth HeAntonio Cubillo GracianAnthony B El-KhoueiryBruno SangroTarek E EldawyJordi BruixGiovanni Luca FrassinetiGina M VaccaroMarina TschaikaChristian ScheffoldPetra KoopmansJaclyn NeelyFabio PiscagliaPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Nivolumab plus cabozantinib with or without ipilimumab showed encouraging preliminary antitumor activity and had consistent safety profiles with those established for the individual drugs in patients with advanced hepatocellular carcinoma.